These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29277791)

  • 1. Strong Prolyl Hydroxylase Domain 1 Expression Predicts Poor Outcome in Radiotherapy-treated Patients with Classical Hodgkin's Lymphoma.
    Bur H; Haapasaari KM; Turpeenniemi-Hujanen T; Kuittinen O; Auvinen P; Marin K; Soini Y; Karihtala P
    Anticancer Res; 2018 Jan; 38(1):329-336. PubMed ID: 29277791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
    Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
    Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
    Bonadonna G; Bonfante V; Viviani S; Di Russo A; Villani F; Valagussa P
    J Clin Oncol; 2004 Jul; 22(14):2835-41. PubMed ID: 15199092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma.
    Bur H; Haapasaari KM; Turpeenniemi-Hujanen T; Kuittinen O; Auvinen P; Marin K; Soini Y; Karihtala P
    Anticancer Res; 2016 Sep; 36(9):4677-83. PubMed ID: 27630312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
    Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.
    Vassilakopoulos TP; Dimopoulou MN; Angelopoulou MK; Petevi K; Pangalis GA; Moschogiannis M; Dimou M; Boutsikas G; Kanellopoulos A; Gainaru G; Plata E; Flevari P; Koutsi K; Papageorgiou L; Telonis V; Tsaftaridis P; Sachanas S; Yiakoumis X; Tsirkinidis P; Viniou NA; Siakantaris MP; Variami E; Kyrtsonis MC; Meletis J; Panayiotidis P; Konstantopoulos K
    Oncologist; 2016 Mar; 21(3):343-53. PubMed ID: 26921291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
    Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
    J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
    J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
    Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
    Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
    Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
    J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
    Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
    J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
    J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
    J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study.
    Jain H; Sengar M; Nair R; Menon H; Laskar S; Shet T; Gujral S; Sridhar E
    J Postgrad Med; 2015; 61(2):88-91. PubMed ID: 25766339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.